Hirotaka Iwaki1,2, Cornelis Blauwendraat1, Hampton L Leonard1,2, Jonggeol J Kim1, Ganqiang Liu3,4,5, Jodi Maple-Grødem6,7, Jean-Christophe Corvol8, Lasse Pihlstrøm9, Marlies van Nimwegen10, Samantha J Hutten11, Khanh-Dung H Nguyen12, Jacqueline Rick13, Shirley Eberly14, Faraz Faghri1,15, Peggy Auinger16, Kirsten M Scott17, Ruwani Wijeyekoon17, Vivianna M Van Deerlin18, Dena G Hernandez1, J Raphael Gibbs1, Kumaraswamy Naidu Chitrala19, Aaron G Day-Williams20,21, Alexis Brice22,23,24, Guido Alves6,7,25, Alastair J Noyce26,27, Ole-Bjørn Tysnes28,29, Jonathan R Evans30, David P Breen31,32,33, Karol Estrada12, Claire E Wegel34, Fabrice Danjou22, David K Simon35,36, Ole Andreassen37,38, Bernard Ravina39,40, Mathias Toft9,41, Peter Heutink42,43, Bastiaan R Bloem10, Daniel Weintraub44,45, Roger A Barker46, Caroline H Williams-Gray46, Bart P van de Warrenburg10, Jacobus J Van Hilten47, Clemens R Scherzer4,5, Andrew B Singleton1, Mike A Nalls1,2. 1. Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, USA. 2. Data Tecnica International, Glen Echo, Maryland, USA. 3. School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong, China. 4. Advanced Center for Parkinson's Disease Research, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA. 5. Precision Neurology Program, Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts, USA. 6. The Norwegian Centre for Movement Disorders, Stavanger University Hospital, Stavanger, Norway. 7. Department of Chemistry, Bioscience and Environmental Engineering, University in Stavanger, Stavanger, Norway. 8. Assistance-Publique Hôpitaux de Paris, ICM, INSERM UMRS 1127, CNRS 7225, ICM, Department of Neurology and CIC Neurosciences, Pitié-Salpêtrière Hospital, Paris, France. 9. Department of Neurology, Oslo University Hospital, Oslo, Norway. 10. Radboud University Medical Centre, Donders Institute for Brain, Cognition, and Behaviour; Department of Neurology, Nijmegen, The Netherlands. 11. The Michael J. Fox Foundation for Parkinson's Research, New York, New York, USA. 12. Translational Genome Sciences, Biogen, Cambridge, Massachusetts, USA. 13. Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA. 14. Department of Biostatistics and Computational Biology, University of Rochester, Rochester, New York, USA. 15. Department of Computer Science, University of Illinois Urbana-Champaign, Champaign, Illinois, USA. 16. Department of Neurology, Center for Health + Technology, University of Rochester, Rochester, New York, USA. 17. Department of Clinical Neurosciences, University of Cambridge, John van Geest Centre for Brain Repair, Cambridge, United Kingdom. 18. Department of Pathology and Laboratory Medicine, Center for Neurodegenerative Disease Research, Parelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA. 19. Laboratory of Epidemiology and Population Sciences, National Institute on Aging, National Institutes of Health, Baltimore, Maryland, USA. 20. Flagship Labs 60 Inc, Cambridge, Massachusetts, USA. 21. Statistical Genetics, Biogen, Cambridge, Massachusetts, USA. 22. Institut du cerveau et de la moelle épinière ICM, Paris, France. 23. Sorbonne Université SU, Paris, France. 24. INSERM UMR1127, Paris, France. 25. Department of Neurology, Stavanger University Hospital, Stavanger, Norway. 26. Preventive Neurology Unit, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, United Kingdom. 27. Department of Clinical and Movement Neurosciences, UCL Institute of Neurology, London, United Kingdom. 28. Department of Neurology, Haukeland University Hospital, Bergen, Norway. 29. University of Bergen, Bergen, Norway. 30. Department of Neurology, Nottingham University NHS Trust, Nottingham, United Kingdom. 31. Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, Scotland. 32. Anne Rowling Regenerative Neurology Clinic, University of Edinburgh, Edinburgh, Scotland. 33. Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, Scotland. 34. Department of Medical and Molecular Genetics, Indiana University, Indianapolis, Indiana, USA. 35. Department of Neurology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA. 36. Harvard Medical School, Boston, Massachusetts, USA. 37. NORMENT, Institute of Clinical Medicine, University of Oslo, Oslo, Norway, Norway. 38. Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway, Norway. 39. Voyager Therapeutics, Cambridge, Massachusetts, USA. 40. Department of Neurology, University of Rochester School of Medicine, Rochester, New York, USA. 41. Institute of Clinical Medicine, University of Oslo, Oslo, Norway. 42. German Center for Neurodegenerative Diseases-Tubingen, Tuebingen, Germany. 43. HIH Tuebingen, Tubingen, Tuebingen, Germany. 44. Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA. 45. Department of Veterans Affairs, Philadelphia, Pennsylvania, USA. 46. Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom. 47. Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands.
Abstract
BACKGROUND: Several reports have identified different patterns of Parkinson's disease progression in individuals carrying missense variants in GBA or LRRK2 genes. The overall contribution of genetic factors to the severity and progression of Parkinson's disease, however, has not been well studied. OBJECTIVES: To test the association between genetic variants and the clinical features of Parkinson's disease on a genomewide scale. METHODS: We accumulated individual data from 12 longitudinal cohorts in a total of 4093 patients with 22,307 observations for a median of 3.81 years. Genomewide associations were evaluated for 25 cross-sectional and longitudinal phenotypes. Specific variants of interest, including 90 recently identified disease-risk variants, were also investigated post hoc for candidate associations with these phenotypes. RESULTS: Two variants were genomewide significant. Rs382940(T>A), within the intron of SLC44A1, was associated with reaching Hoehn and Yahr stage 3 or higher faster (hazard ratio 2.04 [1.58-2.62]; P value = 3.46E-8). Rs61863020(G>A), an intergenic variant and expression quantitative trait loci for α-2A adrenergic receptor, was associated with a lower prevalence of insomnia at baseline (odds ratio 0.63 [0.52-0.75]; P value = 4.74E-8). In the targeted analysis, we found 9 associations between known Parkinson's risk variants and more severe motor/cognitive symptoms. Also, we replicated previous reports of GBA coding variants (rs2230288: p.E365K; rs75548401: p.T408M) being associated with greater motor and cognitive decline over time, and an APOE E4 tagging variant (rs429358) being associated with greater cognitive deficits in patients. CONCLUSIONS: We identified novel genetic factors associated with heterogeneity of Parkinson's disease. The results can be used for validation or hypothesis tests regarding Parkinson's disease.
BACKGROUND: Several reports have identified different patterns of Parkinson's disease progression in individuals carrying missense variants in GBA or LRRK2 genes. The overall contribution of genetic factors to the severity and progression of Parkinson's disease, however, has not been well studied. OBJECTIVES: To test the association between genetic variants and the clinical features of Parkinson's disease on a genomewide scale. METHODS: We accumulated individual data from 12 longitudinal cohorts in a total of 4093 patients with 22,307 observations for a median of 3.81 years. Genomewide associations were evaluated for 25 cross-sectional and longitudinal phenotypes. Specific variants of interest, including 90 recently identified disease-risk variants, were also investigated post hoc for candidate associations with these phenotypes. RESULTS: Two variants were genomewide significant. Rs382940(T>A), within the intron of SLC44A1, was associated with reaching Hoehn and Yahr stage 3 or higher faster (hazard ratio 2.04 [1.58-2.62]; P value = 3.46E-8). Rs61863020(G>A), an intergenic variant and expression quantitative trait loci for α-2A adrenergic receptor, was associated with a lower prevalence of insomnia at baseline (odds ratio 0.63 [0.52-0.75]; P value = 4.74E-8). In the targeted analysis, we found 9 associations between known Parkinson's risk variants and more severe motor/cognitive symptoms. Also, we replicated previous reports of GBA coding variants (rs2230288: p.E365K; rs75548401: p.T408M) being associated with greater motor and cognitive decline over time, and an APOE E4 tagging variant (rs429358) being associated with greater cognitive deficits in patients. CONCLUSIONS: We identified novel genetic factors associated with heterogeneity of Parkinson's disease. The results can be used for validation or hypothesis tests regarding Parkinson's disease.
Authors: Ronald B Postuma; Daniela Berg; Matthew Stern; Werner Poewe; C Warren Olanow; Wolfgang Oertel; José Obeso; Kenneth Marek; Irene Litvan; Anthony E Lang; Glenda Halliday; Christopher G Goetz; Thomas Gasser; Bruno Dubois; Piu Chan; Bastiaan R Bloem; Charles H Adler; Günther Deuschl Journal: Mov Disord Date: 2015-10 Impact factor: 10.338
Authors: David M Altshuler; Richard A Gibbs; Leena Peltonen; David M Altshuler; Richard A Gibbs; Leena Peltonen; Emmanouil Dermitzakis; Stephen F Schaffner; Fuli Yu; Leena Peltonen; Emmanouil Dermitzakis; Penelope E Bonnen; David M Altshuler; Richard A Gibbs; Paul I W de Bakker; Panos Deloukas; Stacey B Gabriel; Rhian Gwilliam; Sarah Hunt; Michael Inouye; Xiaoming Jia; Aarno Palotie; Melissa Parkin; Pamela Whittaker; Fuli Yu; Kyle Chang; Alicia Hawes; Lora R Lewis; Yanru Ren; David Wheeler; Richard A Gibbs; Donna Marie Muzny; Chris Barnes; Katayoon Darvishi; Matthew Hurles; Joshua M Korn; Kati Kristiansson; Charles Lee; Steven A McCarrol; James Nemesh; Emmanouil Dermitzakis; Alon Keinan; Stephen B Montgomery; Samuela Pollack; Alkes L Price; Nicole Soranzo; Penelope E Bonnen; Richard A Gibbs; Claudia Gonzaga-Jauregui; Alon Keinan; Alkes L Price; Fuli Yu; Verneri Anttila; Wendy Brodeur; Mark J Daly; Stephen Leslie; Gil McVean; Loukas Moutsianas; Huy Nguyen; Stephen F Schaffner; Qingrun Zhang; Mohammed J R Ghori; Ralph McGinnis; William McLaren; Samuela Pollack; Alkes L Price; Stephen F Schaffner; Fumihiko Takeuchi; Sharon R Grossman; Ilya Shlyakhter; Elizabeth B Hostetter; Pardis C Sabeti; Clement A Adebamowo; Morris W Foster; Deborah R Gordon; Julio Licinio; Maria Cristina Manca; Patricia A Marshall; Ichiro Matsuda; Duncan Ngare; Vivian Ota Wang; Deepa Reddy; Charles N Rotimi; Charmaine D Royal; Richard R Sharp; Changqing Zeng; Lisa D Brooks; Jean E McEwen Journal: Nature Date: 2010-09-02 Impact factor: 49.962
Authors: Shuchi Mittal; Kjetil Bjørnevik; Doo Soon Im; Adrian Flierl; Xianjun Dong; Joseph J Locascio; Kristine M Abo; Elizabeth Long; Ming Jin; Bing Xu; Yang K Xiang; Jean-Christophe Rochet; Anders Engeland; Patrizia Rizzu; Peter Heutink; Tim Bartels; Dennis J Selkoe; Barbara J Caldarone; Marcie A Glicksman; Vikram Khurana; Birgitt Schüle; David S Park; Trond Riise; Clemens R Scherzer Journal: Science Date: 2017-09-01 Impact factor: 47.728
Authors: Randall J Pruim; Ryan P Welch; Serena Sanna; Tanya M Teslovich; Peter S Chines; Terry P Gliedt; Michael Boehnke; Gonçalo R Abecasis; Cristen J Willer Journal: Bioinformatics Date: 2010-07-15 Impact factor: 6.937
Authors: Albert A Davis; Kristin M Andruska; Bruno A Benitez; Brad A Racette; Joel S Perlmutter; Carlos Cruchaga Journal: Neurobiol Aging Date: 2015-09-30 Impact factor: 4.673
Authors: Christopher G Goetz; Stanley Fahn; Pablo Martinez-Martin; Werner Poewe; Cristina Sampaio; Glenn T Stebbins; Matthew B Stern; Barbara C Tilley; Richard Dodel; Bruno Dubois; Robert Holloway; Joseph Jankovic; Jaime Kulisevsky; Anthony E Lang; Andrew Lees; Sue Leurgans; Peter A LeWitt; David Nyenhuis; C Warren Olanow; Olivier Rascol; Anette Schrag; Jeanne A Teresi; Jacobus J Van Hilten; Nancy LaPelle Journal: Mov Disord Date: 2007-01 Impact factor: 10.338
Authors: Mike A Nalls; Jose Bras; Dena G Hernandez; Margaux F Keller; Elisa Majounie; Alan E Renton; Mohamad Saad; Iris Jansen; Rita Guerreiro; Steven Lubbe; Vincent Plagnol; J Raphael Gibbs; Claudia Schulte; Nathan Pankratz; Margaret Sutherland; Lars Bertram; Christina M Lill; Anita L DeStefano; Tatiana Faroud; Nicholas Eriksson; Joyce Y Tung; Connor Edsall; Noah Nichols; Janet Brooks; Sampath Arepalli; Hannah Pliner; Chris Letson; Peter Heutink; Maria Martinez; Thomas Gasser; Bryan J Traynor; Nick Wood; John Hardy; Andrew B Singleton Journal: Neurobiol Aging Date: 2014-08-04 Impact factor: 4.673
Authors: Ganqiang Liu; Brendon Boot; Joseph J Locascio; Iris E Jansen; Sophie Winder-Rhodes; Shirley Eberly; Alexis Elbaz; Alexis Brice; Bernard Ravina; Jacobus J van Hilten; Florence Cormier-Dequaire; Jean-Christophe Corvol; Roger A Barker; Peter Heutink; Johan Marinus; Caroline H Williams-Gray; Clemens R Scherzer Journal: Ann Neurol Date: 2016-11 Impact factor: 10.422
Authors: Cornelis Blauwendraat; Jose M Bras; Mike A Nalls; Patrick A Lewis; Dena G Hernandez; Andrew B Singleton Journal: Mov Disord Date: 2018-10-09 Impact factor: 10.338
Authors: Amnon A Berger; Ariel Winnick; Jonathan Izygon; Binil M Jacob; Jessica S Kaye; Rachel J Kaye; Elisa E Neuchat; Adam M Kaye; Edward S Alpaugh; Elyse M Cornett; Andrew H Han; Alan D Kaye Journal: Health Psychol Res Date: 2022-06-28
Authors: Dag Aarsland; Lucia Batzu; Glenda M Halliday; Gert J Geurtsen; Clive Ballard; K Ray Chaudhuri; Daniel Weintraub Journal: Nat Rev Dis Primers Date: 2021-07-01 Impact factor: 52.329
Authors: Isabel Alfradique-Dunham; Rami Al-Ouran; Rainer von Coelln; Cornelis Blauwendraat; Emily Hill; Lan Luo; Amanda Stillwell; Emily Young; Anita Kaw; Manuela Tan; Calwing Liao; Dena Hernandez; Lasse Pihlstrom; Donald Grosset; Lisa M Shulman; Zhandong Liu; Guy A Rouleau; Mike Nalls; Andrew B Singleton; Huw Morris; Joseph Jankovic; Joshua M Shulman Journal: Neurol Genet Date: 2021-01-28
Authors: Megan C Bakeberg; Anastazja M Gorecki; Abigail L Pfaff; Madison E Hoes; Sulev Kõks; P Anthony Akkari; Frank L Mastaglia; Ryan S Anderton Journal: NPJ Parkinsons Dis Date: 2021-07-07
Authors: Luis M A Oliveira; Thomas Gasser; Robert Edwards; Markus Zweckstetter; Ronald Melki; Leonidas Stefanis; Hilal A Lashuel; David Sulzer; Kostas Vekrellis; Glenda M Halliday; Julianna J Tomlinson; Michael Schlossmacher; Poul Henning Jensen; Julia Schulze-Hentrich; Olaf Riess; Warren D Hirst; Omar El-Agnaf; Brit Mollenhauer; Peter Lansbury; Tiago F Outeiro Journal: NPJ Parkinsons Dis Date: 2021-07-26